Story perspectives
FDA Approves Vonoprazan: A Game Changer for GERD?
8/5/2025
44 7
1 of 1
Story summary
- The FDA approved Vonoprazan (Voquezna) in 2024 for treating GERD.
- As a potassium-competitive acid blocker (PCAB), it may outperform traditional proton pump inhibitors (PPIs).
- Potential side effects include allergic reactions, kidney issues, and gastrointestinal problems.
- Monthly costs can reach $700 without insurance coverage.
- Consult healthcare providers for personalized information and guidance.
